戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 cancer, but confounding by drug use needs to be followed up.
2 us strains, and development of the infection was followed up.
3  syndrome or controls with related disorders were followed up.
4         Among the 8844 survivors, 8128 (92%) were followed up.
5                                 All patients were followed up 1 year after cardiac arrest.
6  hundred thirty subjects, mean age 61 years, were followed up: 38 with childhood asthma; 53 with chil
7                                        Twins were followed up a median of 32 years between 1943 and 2
8                            The same subjects were followed up after 5 y to determine changes in gluco
9 the 2900 individuals (50.1%) at risk for AMD were followed up after 6 years (mean [SD] age, 60.7 [8.2
10 (4.9%) died in the hospital and 1405 infants were followed up after discharge.
11                       A total of 21 patients were followed up after treatment.
12                                     Patients were followed-up after 14 +/- 4 months.
13  the 93 patients who underwent treatment, 82 were followed-up after transplantation (mean duration, 7
14 ich was followed up in 1989, 1995, and 2001, was followed up again in 2014 when at age 60 to 65 years
15 ntification to determine whether the patient was followed up and, if so, whether treatment was initia
16                                 Participants were followed up and annual hospital costs and admission
17                 Managers and their employees were followed up and reassessed at 6 months after random
18                                     Patients were followed up and reassessed at weeks 6, 12, 36, 52,
19                      A total of 892 contacts were followed up, and blood specimens were collected fro
20                   Five patients continued to be followed up as of March 2017.
21 atients diagnosed as having glaucoma who had been followed up at the Visual Performance Laboratory, U
22                                     Patients were followed up at 1 month, 3 months, 6 months, and 12
23 secutively recruited patients with psoriasis were followed up at 1 year.
24 fant pairs; of these, 13557 children (79.5%) were followed up at 16 years of age between September 20
25  of 26,184 pregnant women and their children were followed up at 2-year intervals until the age of 6
26   Participants were assessed at baseline and were followed up at 3, 6, and 9 months.
27 ed, longitudinal HealthNuts Study (n = 5276) were followed up at 4 years of age with repeat oral food
28 Jan 1, 2013, and March 31, 2013, all of whom were followed up at 4 years of age.
29                                     Patients were followed up at 6 months and 1 year after randomisat
30 opulation of all randomised participants who were followed up at 6 months.
31 y 2007 and June 2012 in Victoria, Australia, were followed up at 6, 12, and 24 months after injury to
32 ster dose; 67 of 75 study vaccine recipients were followed up at 8 months.
33 ngletons in a population-based birth cohort) were followed up at age six and half years.
34                                      Infants were followed up at ages 6 (n = 2956) and 12 (n = 2872)
35                               These subjects were followed up at least for 12 months.
36 -onset ADAD and 12 noncarrier family members were followed up at the Knight Alzheimer Disease Researc
37                       This group of patients was followed up beginning on their 15th birthday until t
38                     Myocardial contractility was followed up by cardiac magnetic resonance (CMR) and
39                                 Disc quality was followed up by magnetic resonance imaging.
40                         Respiratory outcomes were followed up by questionnaires until age 5, when for
41 uritis (49 females, mean age 33.5 years) and were followed up clinically 2 and 5 years later.
42 s of current asthma was ultimately ruled out were followed up clinically with repeated bronchial chal
43          Patients with celiac disease should be followed up closely for dietary adherence, nutritiona
44 atric eyes with noninfectious uveitis should be followed up closely for IOP elevation, especially whe
45                         Such patients should be followed up closely to monitor the treatment response
46                         Such patients should be followed up closely to prevent fast lung function dec
47 h up to 3 individuals who continued PI, were being followed up during the calendar period of the swit
48 ed doses or a single dose of albendazole and were followed up during 13 months to assess the incidenc
49                    After DAT-SPECT, patients were followed up during 5.7 +/- 2.2 (range, 2.6-9.9) yea
50 ed influenza vaccine (IIV3) during pregnancy were followed up during the first 6 months of life for p
51 ndividuals born in Denmark from 1955 to 2012 were followed up during the study period (total follow-u
52                     Two hundred ten patients were followed up every 3 months, with a mean follow-up o
53                                 Participants were followed up every 6 months, and data at the baselin
54 rom the English Longitudinal Study of Ageing were followed-up every two years until they reported a d
55 atients in the single-drug doxorubicin group were followed up expectantly whereas patients with stabl
56                        These patients should be followed up for a prolonged time to determine whether
57                        All the patients will be followed-up for a maximum of 6 months.
58 o had undergone one of the interventions and been followed up for at least 1 year.
59                                      She was being followed up for mild hypercalcemia (calcium level,
60 All patients not on active study therapy are being followed up for survival.
61                                  ABPA status was followed up for 1 year.
62 d 185 deaths and the control treatment group was followed up for a mean 128 days and had 87 deaths.
63                 The long-acting opioid group was followed up for a mean 176 days and had 185 deaths a
64                A cohort of 770 pCIS patients was followed up for at least 10 years.
65                                  The patient was followed up for clinical and radiologic regression o
66                      In addition, the cohort was followed-up for the onset of clinical Parkinson's di
67 mab (n = 5007) or not (n = 2829) at baseline were followed up for </=5 years.
68      Patients with a graft rejection episode were followed up for 1 additional year.
69                            Clinical outcomes were followed up for 1 year and included evaluation of p
70  meningoradiculitis (Bannwarth syndrome) who were followed up for 1 year at a single center.
71  on the basis of PA:A ratio (>1 or </=1) and were followed up for 1 year in the derivation cohort and
72 week socioeconomic intervention, of whom 231 were followed up for 1 year.
73 at a single center between 1986 and 2014 and were followed up for 1 year.
74 unctional disability and all-cause mortality were followed up for 1,374 d (follow-up rate = 96.1%).
75 (fMRI) before making a quit attempt and then were followed up for 10 weeks after their quit date.
76                                     Patients were followed up for 10 years.
77                                     Patients were followed up for 12 months after stricture resolutio
78                                 Participants were followed up for 12 months with masked outcome asses
79 ition) subthreshold depression; participants were followed up for 12 months.
80                                     Patients were followed up for 12 months.
81                                 All patients were followed up for 12 months.
82                                 Participants were followed up for 12 months.
83                                 Participants were followed up for 12.5 years, with 57 incident CHD ev
84                                     Patients were followed up for 14 months.
85  range, 44-100 years; 56% female; 77% white) were followed up for 14.0 years (median).
86               Two hundred fifty-six patients were followed up for 16.3+/-3.8 months.
87 ins, Zn+MVs, or a placebo at 6 wk of age and were followed up for 18 mo with monthly growth measureme
88 dents who were 15 years or older (N = 77774) were followed up for 2 years (2013-2014 to 2015-2016).
89                                     Patients were followed up for 2 years (up to April 2013) and 215
90 -seeing eye, at either of 2 dose levels, and were followed up for 2 years after treatment.
91                                     Subjects were followed up for 2 years from intervention.
92 Foundation Trust in London, UK, 245 patients were followed up for 2 years from the onset of first-epi
93 from 2000 to 2011 (n = 1375) in our hospital were followed up for 2 years, evaluating 3 time periods.
94                                     Patients were followed up for 2 years.
95 0 mg/mL) injections given 2 weeks apart, and were followed up for 2 years.
96 nger than 6 years with a first or second UTI were followed up for 2 years.
97                             All participants were followed up for 2 years.
98 nt of Aortic Transcatheter Valve 2 Trial and were followed up for 2 years.
99 e studies included 1 005 791 individuals who were followed up for 2-18.1 years, during which 84 609 (
100                                     Patients were followed up for 2.3+/-1.1 years.
101                                 Participants were followed up for 21 days to determine pneumococcal c
102 n consisted of 5205 individuals with HIV who were followed up for 24 031 person-years.
103                                MECs patients were followed up for 25-69 months after surgery, present
104 andard care, versus standard care alone, and were followed up for 28 days.
105 tamivir) twice a day for 5-10 days; patients were followed up for 28 days.
106 y for 5 days, given orally, and participants were followed up for 28 days.
107 ging Municipal Employees (FLAME) in 1981 and were followed up for 28 years.
108                                 Participants were followed up for 3 and 10 years for falls leading to
109                                 All patients were followed up for 3 months before transplantation and
110                                     Patients were followed up for 3 years.
111      A total of 277 eyes of 188 participants were followed up for 3.7 +/- 2.1 years.
112  consecutive ambulatory patients with HF who were followed up for 4.1 years.
113 from May 30, 2011, to December 11, 2014, and were followed up for 42 days after treatment.
114                                     Patients were followed up for 42 days during the years 2009-15.
115 SAPPHIRe) family study, and 759 participants were followed up for 5 years.
116          A total of 136 eyes of 123 patients were followed up for 57.7 +/- 16.2 months.
117                                 Participants were followed up for 6 months.
118 y before the transplant surgery and patients were followed up for 6 months.
119                                 Participants were followed up for 6 years, with biannual visits inclu
120                                     Subjects were followed up for 7.5 years.
121                                     Patients were followed up for 8 weeks (all patients) and up to 76
122  adults and 194 children), and all vaccinees were followed up for 84 days.
123 ated antiretroviral therapy in 2004-2005 and were followed up for 9 years, we calculated patients' ti
124                                     Patients were followed up for a mean (SD) of 26.7 (2.7) months (r
125               Patients with cataract surgery were followed up for a mean of 11.4 quarters (standard d
126 ), whereas patients without cataract surgery were followed up for a mean of 12.9 quarters (SD, 12.2 q
127                        223 880 men and women were followed up for a mean of 13 years (SD 6).
128                            Glaucoma patients were followed up for a mean of 3.90 years (range, 2.03-5
129                                    All women were followed up for a mean of 38.8 months to analyze da
130 m February 7, 2005, to January 15, 2013, and were followed up for a mean of 4.1 years through the stu
131 We recruited 2404 adult patients with FH who were followed up for a mean of 5.5 years (SD, 3.2 years)
132 2%) of whom had also made a suicide attempt, were followed up for a mean of 5.6 years.
133 ood Frequency Questionnaire in 1993-1997 and were followed up for a median of 10 y.
134                                     Patients were followed up for a median of 10.4 months (IQR 8.6-13
135                                  Individuals were followed up for a median of 14.6 years.
136                           Study participants were followed up for a median of 17.4 years (range, 0.1-
137                                     Patients were followed up for a median of 2.6 years (IQR 2.0-3.2)
138                                 601 children were followed up for a median of 2.9 years (IQR 1.5-4.4)
139                        Transplanted patients were followed up for a median of 22 months by use of ser
140                           These participants were followed up for a median of 33 months (study start
141 ticipants chose to start open-label PrEP and were followed up for a median of 335 days (IQR 0-364).
142        Thirty-five patients underwent LT and were followed up for a median of 38 months.
143                                     Patients were followed up for a median of 4.5 years.
144                                     Patients were followed up for a median of 5.0 years (IQR 3.4-6.0)
145                                 Participants were followed up for a median of 5.6 years (range 0.3-20
146 ange, 40.0-61.0 years; 1354 men [51.0%]) and were followed up for a median of 5.6 years, 470 patients
147 iously hospitalized with S aureus bacteremia were followed up for a median of 7.8 years (interquartil
148 iversity Hospital during 1992-2013 (n = 399) were followed up for a median of 7.8 years.
149 s from debridement; patients without failure were followed up for a median of 802 days.
150 ween May 21, 2005, and Dec 1, 2015, patients were followed up for a median of 83 months (IQR 69-94 mo
151                                     Patients were followed up for a minimum of 24 months.
152                        Eighty-three patients were followed up for a minimum of 3 years, with a local
153                                     Patients were followed up for an additional 2 weeks.
154 ad preserved ejection fraction; and patients were followed up for an average of 333+/-125 days.
155 , and had no previous cancer at recruitment, were followed up for an average of 4.9 years from April
156 w-up started at age 1 year, and the children were followed up for as long as 10.7 years (median, 5.5
157 cognitive impairment at first assessment who were followed up for as long as 36 years (mean [SD], 12.
158  adolescents who visited the draft board and were followed up for as much as 25.4 years from draft bo
159 with single-dose azithromycin (30 mg/kg) and were followed up for assessment of clinical resolution.
160                                 All patients were followed up for at least 1 year, or had a censoring
161                                     Patients were followed up for at least 1 year.
162                                     Patients were followed up for at least 12 months; median follow-u
163                                     Patients were followed up for at least 2 visits after enrollment.
164 d final analysis occurred after all patients were followed up for at least 21 months.
165                                     Patients were followed up for at least 6 months and for up to 33
166 I posterior who received IVB monotherapy and were followed up for at least 65 weeks adjusted age (AA)
167                                 Participants were followed up for clinical events through central reg
168 acy included two large regional cohorts that were followed up for dengue infection.
169                                     Children were followed up for diagnoses of ASD (International Cla
170  in Denmark and Sweden between 1987 and 2012 were followed up for diagnosis of thromboembolism and ar
171             Cancer survivors and comparisons were followed up for hospitalizations in the Danish Pati
172                                 Participants were followed up for incident cancer diagnoses, which we
173 nts a mean (SD) of 5.9 (0.6) years apart and were followed up for incident dementia throughout the st
174                                 All patients were followed up for major adverse cardiac events (MACE)
175                   Of the 1585 patients, 1175 were followed up for more than 1 year after PVI.
176 Failure Registry (SwedeHF) from 2003 to 2011 were followed up for mortality predictors and longevity.
177 echocardiography, and 6-minute walk test and were followed up for mortality until the end of December
178                                         They were followed up for over 48 months for function of the
179                          A total of 368 SNPs were followed up for replication.
180                                    The women were followed up for respiratory illness from midpregnan
181  3 in Europe (Finland, Germany, and Sweden), were followed up for T1DM-related autoantibodies.
182                 108 participants with pre-DM were followed up for ten years and divided into 3 groups
183                                     Patients were followed up for the composite end point of death, u
184                                     Patients were followed up for the primary outcome of 28-day morta
185                             All participants were followed up for up to 1 year.
186                                     Patients were followed up for up to 1 year.
187 types for celiac disease and type 1 diabetes were followed up for up to 20 years for development of t
188  of the 12-month study, a subset of patients were followed up for up to 24 months.
189                                 Participants were followed up for up to 5 years after their last annu
190                             All participants were followed up for up to 5.3 years (median, 3.2 years)
191 ral regurgitation had baseline CMR scans and were followed up for up to 8 years (mean, 2.5+/-1.9 year
192 s with symptomatic small vessel disease, who were followed-up for >/=1 years.
193 kg agalsidase-alpha (switch group, n=37) and were followed-up for 2 years.
194                          Total 323175 adults were followed-up for 96 (60-120) (median [5-95%]) months
195                                 Participants were followed-up for CVD mortality after linkage to nati
196                             All participants were followed-up for medically certified cardiac events
197 NPs are new for serum metabolite levels, and were followed-up for replication in an independent sampl
198 nformation about childhood bullying behavior was followed up from 8 to 29 years of age.
199 ween January 1, 1979, and December 31, 2001, was followed up from age 6 years to December 31, 2009 (N
200    Three hundred thirty-seven adult patients were followed up from 1 to 36 months after kidney transp
201 viduals born in Sweden from 1987 to 2012 who were followed up from 1 year of age to December 31, 2013
202 en from Health Professionals Follow-Up Study were followed up from 1984 to 2012 and from 1986 to 2010
203 ntal information from national registers who were followed up from birth throughout 2014.
204 members of the New Zealand Dunedin Study who were followed up from birth until ages 18 and 38 years,
205 members of the New Zealand Dunedin Study who were followed up from birth until ages 18 and 38 years,
206 rdiovascular Risk in YFS (Young Finns Study) were followed up from childhood (age 3-18 years) to adul
207                        A total of 1016 women were followed up from gestational week 17 to delivery.
208                             All participants were followed up from inclusion in the studies to Novemb
209                                         They were followed up from January 1, 1973, until December 31
210 ed 15 to 34 years who were living in Denmark were followed up from January 1, 2000, to December 2013,
211  3 million people born between 1955 and 2006 were followed up from January 1, 2002, through December
212                            Medicare patients were followed up from procedure date until death, stroke
213               All patients without prior AMD were followed up from the date of diagnosis (or correspo
214           Subsequently, 16 sequence variants are followed up in a diverticular disease sample from De
215 l as low-risk patients who could potentially be followed up in primary care.
216 cruited in 1964 at age 10 to 15 years, which was followed up in 1989, 1995, and 2001, was followed up
217 e participants (age, >/=40 years; 2006-2008) were followed up in 2011 through 2013, and 1901 of 3280
218 al of 82 variants with p-value </=1 x 10(-5) were followed up in 373 African Americans.
219                               These findings were followed up in a specifically selected cohort, in w
220                Promising association signals were followed up in additional data sets (of 14,545 or 7
221                                 Participants were followed up in hospital wards and at 3 and 6 months
222                                  Individuals were followed up in the nationwide Psychiatric Central R
223                           115 of these cases were followed up in the survey.
224                The three associated variants were followed-up in the Chinese cohort; one SNP rs170183
225 of 435 patients without dementia at 6 months were followed up longitudinally (median follow-up, 47.4
226 e LA function in 308 patients with HFpEF who were followed up longitudinally for adverse outcomes.
227 rithm 30-2 Standard or Fast), and 36 of them were followed up (median interval, 10 months after basel
228 orally once daily for 3 months, and patients were followed up monthly for 4 months.
229  mycophenolate mofetil, 1 g twice daily, and were followed up monthly for 6 months.
230 VD, which suggests that these persons should be followed up more closely to prevent CVD.
231  was 97.9 (85.8) months; 83 patients (91.2%) were followed up, of whom 37 (44.58%) experienced a recu
232 re pre-emptive antiviral therapy, but should be followed up on a monthly basis for alanine aminotrans
233                                     Patients were followed up on a 6-monthly basis for reassessment a
234                                     Patients were followed up on days 1, 7, and 28 and then every 2 m
235                                     Subjects were followed up over a maximum of 113 d.
236                   A total of 7542 recipients were followed up over a median follow-up time of 5.3 yea
237 Sept 30, 2012, 2 010 398 cohort participants were followed up over a median of 8.52 years (IQR 8.05-8
238 ond extensively drug-resistant tuberculosis, were followed up over a period of 6 years.
239 the skin in a cohort of 217 participants who were followed up over the first 2 rounds of biannual tre
240                                 Participants were followed up prospectively for SCC development.
241 n whom active tuberculosis developed and who were followed up prospectively.
242 3 of 22 focused on how often patients should be followed up (re-examination) and treatment effectiven
243 ssed by electroencephalography; 202 patients were followed up regarding the occurrence of overt HE an
244 ween January 1, 2004, and December 31, 2011, was followed up through December 31, 2012, to study the
245                                    The women were followed up through 2009.
246                                 Participants were followed up through 2012 with a 99% successful foll
247                                 Participants were followed up through December 31, 2010.
248 m January 1, 1973, to December 31, 1996, who were followed up through December 31, 2013.
249  January 1, 2008, and December 31, 2012, and were followed up through December 31, 2013.
250 1, 2010, and no prior HF; study participants were followed up through March 31, 2013.
251 en June 19, 2003, and September 3, 2008, and were followed up through March 31, 2013.
252                                     Patients were followed up through to Dec 31, 2014.We assessed the
253                                 Participants were followed-up through 2012 to assess incident frailty
254 se who develop postoperative delirium should be followed up to enable early detection of dementia sym
255  the basis of data from 213 patients who had been followed up to autopsy and met inclusion criteria o
256                                         They were followed up to 18 to 19 years of age, with 81.3% re
257 049 newborns were enrolled, and 9336 (77.5%) were followed up to 2 years of age.
258                               Remaining mice were followed up to 22 months.
259                                     Patients were followed up to 3 years.
260 itudinal Study and Normative Aging Study who were followed up to 33 y from 1981 to 2013.
261           In addition, 346 eligible children were followed up to assess reactions to subsequent use o
262 %) newborn babies in the dry cord care group were followed up to day 28 or death.
263                                     Patients were followed up to days 28-35 after first dose.
264 t between Jan 1, 2007, and Dec 31, 2013, and were followed up to Dec 31, 2014 (end of study).
265 ed between September and December, 2016, who were followed up to detect whether they developed cutane
266  over the stroke-affected gastrocnemius) and were followed up to poststroke d 14.
267 lder who were cognitively normal at baseline were followed up to the outcome of incident MCI.
268 e, 74-82 years]; 50.4% [n = 973] female) who were followed up to the outcome of incident MCI.
269 rth American Prodrome Longitudinal Study who were followed up to the time of conversion to psychosis
270 clefts and 1 413 819 unaffected individuals, was followed up until December 31, 2010, using compulsor
271                                   The cohort was followed up until September 30, 2012.
272 , to women with a history of CS (n = 40,145) were followed up until 31 January 2015.
273 the quadrivalent meningococcal vaccine group were followed up until age 6 months.
274                                     Patients were followed up until August 2015 (complete follow-up t
275                                     Patients were followed up until day 30.
276                                 All patients were followed up until day 42.
277                                     Patients were followed up until death or were censored on Decembe
278 tal of 309 patients (309 eyes) with glaucoma were followed up until death; 203 patients (65.7%) had p
279   All people living in Spain on Nov 1, 2001, were followed up until Dec 31, 2011.
280 ish registers, cases, siblings, and controls were followed up until December 31, 2011.
281  in 1999 with an acute head trauma (n = 737) were followed up until February 2014 and compared with a
282 patients, 1,211 with chronic kidney disease, were followed up until hospital death or discharge.
283                                     Patients were followed up until hospital discharge or death.
284                   Subsequently, participants were followed up until January 1, 2015, for the onset of
285                                     Children were followed up until March 31, 2014.
286 ance between January 2012 and April 2015 and were followed up until November 2015.
287                  The imaging characteristics were followed up until the occurrence of PML-IRIS.
288                                 Participants were followed up until their death or November 24, 2014.
289                    A total of 418,057 adults were followed-up using a nationwide prospective cohort s
290 n, including 24-h respiratory recording, and were followed-up using cardiac mortality as an endpoint.
291 lywise error cluster-level corrected p<0.05) were followed up via Tukey-corrected pairwise comparison
292 gible patients (308 patients [96.9%] of whom were followed up) were older and had more advanced disea
293 ory-confirmed cases of meningococcal disease are followed up with PHE local health protection teams,
294      This is a preliminary report that would be followed up with information on medium and long term
295  December 2002 and December 2011 and who had been followed up with imaging and clinical evaluation fo
296                                     Patients were followed up with contrast-enhanced CT every 2-4 mon
297      Nodules without pathologic confirmation were followed up with MR imaging every 6 months.
298                                     Children were followed up with telephone calls and an in-person v
299                    16,908 (84%) participants were followed up with the 16 week questionnaire (8241 in
300 icant differences in the ROI-to-ROI analysis were followed up with voxelwise seed-based analyses to f

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top